Mark Manfredi - 03 Feb 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
President & CEO, Director
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Mark Manfredi
Issuer symbol
IKNA
Transactions as of
03 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 17:12:13 UTC
Next filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +238,900 $0.000000 238,900 03 Feb 2022 Common Stock 238,900 $9.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.